Shots:

• The opinion is based on P-II CheckMate -142 study assessing Opdivo + Yervoy in patients with mismatch repair deficient or microsatellite instability–high metastatic colorectal cancer whose disease had progressed during or after prior treatment with CT
• If approved- Opdivo in combination with Yervoy will be the first dual immunotherapy approved in the EU in gastrointestinal cancer
• The combination regimen receives the US FDA’s approval in Jul’2018 for adults and pediatric patients aged ≥12yrs. with MSI-H or dMMR mCRC that has progressed following treatment with CT. The dual regimen receives PMDA approval in Sept’2020 for MSI-H unresectable- advanced or recurrent colorectal cancer progressing after CT

  Ref: BMS | Image: BMS